Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $80.91 USD
Change Today 0.00 / 0.00%
Volume 0.0
SHPGF On Other Exchanges
Symbol
Exchange
SHPGF is not on other exchanges.
As of 8:10 PM 03/25/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHPGF) Key Developments

Shire plc Announces Availability of New Titration Strength of ADHD Drug

Shire plc has announced the availability of Vyvanse 10mg capsules indicated for the treatment of attention-deficit/hyperactivity disorder, or ADHD. This new titration dose, which was approved by the FDA on October 30, 2014, is the seventh Vyvanse dosage strength available in addition to the 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsule strengths. In July 2014, Shire received approval for two additional administration options for Vyvanse capsules. In addition to swallowing whole or mixing the capsule contents with water, the contents can be mixed with yogurt or orange juice for patients who have trouble swallowing capsules.

Shire Reportedly Mulls Acquisition Of Ironwood Pharmaceuticals

Shire plc (LSE:SHP) is reportedly seeking acquisition of Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD). Market sources reported that Ironwood Pharmaceuticals has been approached by European suitors, including Shire, 35p better at 5635p, and rejected cash offers in the region of $30 a share. Ironwood Pharma jumped 5% to $16.47.

Genfit Reportedly Mulls Sale

Genfit SA (ENXTPA:GNFT) is reportedly exploring the option of selling itself. According to people familiar with the matter, Genfit SA has also held preliminary discussions with potential strategic buyers. According to the sources, Genfit has yet not made a any decision and there is a possibility that it may not sell at all. The potential buyers include Sanofi (ENXTPA:SAN), Shire plc (LSE:SHP) and Novartis AG (SWX:NOVN).

Shire plc Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults

Shire plc announced that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. The NDA submission is supported by the totality of evidence from four clinical trials with more than 1,800 patients. These included one Phase 2 study, two Phase 3 efficacy and safety studies, and one long-term Phase 3 safety study.

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $80.91 USD 0.00

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.70 AUD -1.85
Eisai Co Ltd ¥8,918 JPY -132.00
Hospira Inc $87.91 USD +0.16
Mylan NV $62.07 USD +0.84
UCB SA €67.62 EUR -0.63
View Industry Companies
 

Industry Analysis

SHPGF

Industry Average

Valuation SHPGF Industry Range
Price/Earnings 14.5x
Price/Sales 7.8x
Price/Book 5.4x
Price/Cash Flow 13.9x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.